INNOVATIVE DRUG DAILY· NO.002一、BD 交易与授权合作 / BD Deals & Licensing
中文|周末授权交易清淡,但三则「非典型」信号值得记录。其一,熙源安健与艾伯维的偏头痛临床前资产交易金额首次明确为潜在总额最高 7.57 亿美元——第017期仅确认了交易存在而未披露对价,本次补上了金额锚点,也说明 MNC 对中国临床前偏头痛/CGRP 周边资产的定价已进入「亿美元级」。其二,德国 Vivoryon 从先声药业手中收回其肾脏病在研资产的中国权益,公司现金储备接近枯竭;这是本月第二笔「反向交易」(前有百奥泰 5,000 万元收回 BAT1706 中国权益),提示中国 BD 已从单向「买进来」进入双向流动阶段。其三,中国生物制药在 11-05 业绩会上披露,与勃林格殷格翰 70 亿美元交易的 3.58 亿美元首付款及近期付款自 2027 年起入账、绝大部分于 2027 年确认收入,并预告「12 月还有好消息」——首付款确认时点直接决定 2026 年报与 2027 年报的收入节奏,值得作为财务模型的关键假设。资本端,EQT Life Sciences 等欧洲十大生命科学投资机构组团赴上海浦东对接中国管线,中欧 Biotech 的授权与股权撮合通道正在变宽。
English|The weekend produced no new large license-out, but three atypical signals are worth logging. First, the migraine preclinical deal between Xiyuan Anjian and AbbVie was for the first time sized atup to $757 million in total potential value— Issue 017 confirmed the deal without disclosing economics, and the new figure anchors Big Pharma's pricing of Chinese preclinical migraine/CGRP-adjacent assets at the hundred-million-dollar level. Second, Germany's cash-strapped VivoryonregainedChina rights to its kidney-disease prospect from Simcere — the second "reverse deal" this month after Bio-Thera paid RMB 50 million to buy back BAT1706 China rights — a sign that China BD has moved from one-way in-licensing to two-way asset flow. Third, Sino Biopharmaceutical said on its 5 November earnings call that the$358 million upfront and near-term paymentsfrom its $7 billion Boehringer Ingelheim pact will begin to be bookedfrom 2027, with the bulk recognized that year, adding that "more good news" is due in December; the timing of upfront recognition directly shapes 2026 and 2027 revenue. On the capital side, ten European life-science investors led by EQT Life Sciences travelled to Shanghai's Pudong to screen Chinese pipelines, widening the China–Europe licensing and equity matchmaking channel.
交易/事件
交易方
金额与结构
备注
偏头痛临床前资产授权
熙源安健 → 艾伯维
潜在总额最高 7.57 亿美元
017 期已确认交易,本期首次明确金额
中国权益回收
先声药业 → Vivoryon
未披露
德方现金接近枯竭,属「反向交易」
6 个临床前 ADC/TCE
中国生物制药 → 勃林格殷格翰
70 亿美元(首付 3.58 亿)
首付 2027 年起确认,12 月另有预告
欧洲 LP 组团来华
EQT Life Sciences 等 10 家
—
浦东对接,中欧撮合通道拓宽二、药企信息与战略动向 / Corporate Strategy & Company News
中文|本期最重的一条是辉瑞的管线大清仓。据 Insight 数据库 11-08 周报与智慧芽梳理,辉瑞在 Q3 业绩文件中一次性终止 7 个临床项目:减重端,刚进临床的 PF-07999415 被砍,自 Metsera 收购而来的 PF-08654696 与 PF-08653944 联合疗法叫停,GIPR 激动/拮抗双向布局全部清零;肿瘤端,两项泛 KRAS 资产同步放弃,KRAS 赛道管线归零。这与前三季度 43.25 亿美元资产减值(其中约 38 亿来自肺癌 ADC sigvotatug vedotin 的 III 期 OS 失败)构成同一条叙事:辉瑞正在为 2023—2025 年的外部扫货付学费,并把资源向超长效与联合减重集中。对照之下,中国同一批靶点正被 MNC 以 20 亿美元级筹码反复押注——「辉瑞退出的赛道,恰是中国被抢的赛道」是本期最锋利的一句行业注脚。
其余动向:Moderna 实现两年来首次季度盈利(Q3 营收 13 亿美元、+29%,净利 1.62 亿美元),全年营收增速指引上调至 15%—25%,重心转向个体化肿瘤疫苗;诺和诺德长期 CFO 离任,财务班子进入交接;阿斯利康任命赛诺菲老将 Hunt Mayo 执掌体重管理商业化(常驻波士顿),配合口服 GLP-1 elecoglipron 未来 1—2 年的关键读出,属「数据未出、商业化先卡位」。中国侧,百利天恒完成董秘与 CFO 新老交替(71 岁张苏娅二度出山任董秘、38 岁黄应娟接任 CFO),艾力斯董秘李硕辞职由董事长代行;华东医药因围标串标被暂停全军采购资格(11-06 军队采购网公示,法定代表人吕梁及授权代表孟杰控股/管理企业一并受限),成为招投标合规的新标本;微创系四家公司停牌逾两月,中小股东公开致信要求将复牌列为最高优先级。商业化侧,Revolution Medicines 的 daraxonrasib(Rasonque)上市前五周销售 1.98 亿美元、覆盖约 5,000 例患者,超出卖方预期。
English|The heaviest corporate story isPfizer's pipeline purge. Per Insight's 8 November weekly and Synapse's review, Pfizer terminated seven clinical programmes in its Q3 filing: in obesity, the just-started PF-07999415 was dropped and the Metsera-derived PF-08654696/PF-08653944 combination was stopped, leaving no active GIPR agonist or antagonist programme; in oncology, two pan-KRAS assets were abandoned, emptying its KRAS pipeline. This sits on the same narrative as the $4.325 billion of impairment booked in the first nine months (about $3.8 billion from the Phase 3 overall-survival failure of lung-cancer ADC sigvotatug vedotin): Pfizer is paying tuition for its 2023–2025 shopping spree while concentrating resources on ultra-long-acting and combination obesity drugs. The contrast is sharp — the very targets Pfizer just vacated are the ones Big Pharma is paying $2 billion-plus to license from China.
Elsewhere:Moderna posted its first quarterly profit in two years(Q3 revenue $1.3 billion, +29%; net income $162 million), lifted full-year revenue growth guidance to 15–25% and pivoted toward personalized cancer vaccines;Novo Nordisk's long-serving CFO departed;AstraZeneca named Sanofi veteran Hunt Mayo to lead obesity commercialisation(based in Boston), pre-positioning ahead of key oral GLP-1 elecoglipron readouts in one to two years. In China,Baili Tianhengreshuffled board secretary and CFO (71-year-old Zhang Suya returning as board secretary, 38-year-old Huang Yingjuan as CFO) andAkeso-peer Allistlost its board secretary;Huadong Medicine was suspended from all military procurementon 6 November for bid-rigging, with its legal representative and authorised agent's affiliated companies also barred — a new template for tender-compliance risk; and thefour MicroPort entities remained halted for a third month, with minority shareholders publicly demanding that resumption be made the top priority. Commercially, Revolution Medicines' daraxonrasib (Rasonque) generated $198 million in its first five weeks, reaching roughly 5,000 patients and beating sell-side expectations.三、全球政策与监管 / Global Policy & Regulation
中文|美国本周进入「规则落地季」,且集中在支付端。CMS 于 11-04 发布最终规则,2027 年起大幅削减 340B 项目药品支付并扩大「站点中立」支付,医院协会强烈反对——这意味着同一药品在院内不同场景的支付差将被抹平,对高值注射剂与肿瘤药的渠道经济学影响直接。劳工部同步敲定PBM 费用披露规则,2027 年起药品中间商须向自费雇主客户披露费用与报酬数据。HHS 则宣布不对 6 种未获批肽类产品执法,等于为配制商开了口子,延续了「以执法裁量替代审批」的路径。KFF 测算 2027 年Medicare Part D 保费平均上涨约 50%,在开放参保期提醒老年人比价。中期选举后,卖方普遍预期生物医药板块在「blue wave」下表现更优,理由是民主党掌控国会的优先级在生活成本与医保覆盖,药价立法短期难落地。
中国侧,医保「双目录」进入最后倒计时:124 个目录外药品已完成谈判、12 个创新药完成商保价格协商,新版目录预计 11 月底前公布、2027-01-01 执行,11-14 苏州全国创新药高质量发展大会将公布新增名单。今年首次实现双目录衔接,药明巨诺瑞基奥仑赛依托商保目录「条件五」进入基本医保谈判,百万元级 CAR-T 首次坐上国家谈判桌——这是分层支付从制度设计走向价格发现的关键一步。监管侧,国家卫健委、国家中医药局时隔 8 年修订《罕见病目录制订工作程序(2026 年版)》,明确病种纳入条件、申请主体与材料要求并扩大覆盖;卫健委通报第六批「论文工厂」12 起案件,涉 10 家医院,追责延伸至十年前且覆盖「未发表也追责」。CDE 副主任余欢 11-08 在虹桥论坛确认,创新药临床试验审评已跑通「30 日通道」,与 60 日默示许可形成双通道并行,并明确境外已上市原研药/仿制药境内申报、经原辅包平台登记的进口原料药可走优先审评。
English|The US entered a rule-finalisation season concentrated on the payment side. CMS issued a final rule on 4 Novembercutting 340B drug payments substantially and expanding site-neutral payments from 2027, drawing fierce hospital opposition — the payment gap between hospital outpatient and physician-office settings narrows, with direct consequences for the channel economics of high-cost injectables and oncology drugs. Labor simultaneously finalised aPBM disclosure rulerequiring drug middlemen to share fee and compensation data with self-funded employer clients from 2027. HHS said itwill not enforce against six unapproved peptides, effectively opening a door for compounders and extending a pattern of substituting enforcement discretion for approval. KFF estimatesMedicare Part D premiums will rise about 50% on average in 2027, urging seniors to compare plans during open enrolment. Post-midterms, sell-side analysts expect biopharma to outperform under a "blue wave", reasoning that Democrats' priorities are cost of living and coverage rather than near-term drug-pricing legislation.
In China, thedual catalogues are in their final countdown: 124 out-of-list drugs have completed negotiation and 12 innovative drugs finished commercial-insurance price negotiation, with the new editions due by end-November and effective 1 January 2027; the14 November Suzhou national innovative-drug conference will unveil the new additions. For the first time the two catalogues are linked, and JW Therapeutics' relma-cel entered basic-medicare negotiation via the commercial-insurance catalogue's "Condition 5" — thefirst million-yuan-class CAR-T to sit at the national negotiating table, a pivotal step from system design to price discovery. Regulators: the NHC and NATCMrevised the working procedure for the rare-disease catalogue after eight years, clarifying inclusion criteria, applicant eligibility and materials while broadening coverage; the NHC announced12 cases in its sixth "paper mill" crackdownacross 10 hospitals, with liability reaching back a decade and extending to unpublished papers. CDE deputy director Yu Huan confirmed on 8 November that a30-day clinical-trial review channelnow runs in parallel with the 60-day tacit-approval pathway, with priority review opened to overseas-approved originators and generics filed domestically, and to imported APIs registered via the excipient/packaging platform.四、临床进展与监管批准 / Clinical Progress & Approvals
中文|本期头条是Vir Biotechnology 的丁型肝炎组合疗法 ECLIPSE 1 III 期成功,11-08 以口头报告形式在 AASLD 2026 公布。研究纳入 124 例慢性丁肝(CHD)患者、2:1 随机,每月皮下注射 elebsiran(siRNA)+ tobevibart(抗 HBsAg 单抗)对比延迟治疗(第 12 周起始):主要终点(第 48 周 HDV RNA 不可检出 + ALT 复常)44% vs 0%(p<0.0001),关键次要终点(单纯病毒不可检出)79% vs 0%;肝硬化和非肝硬化患者分别达85%(n=46)与 73%(n=37),提示疗效不被肝硬化状态削弱。安全性方面仅 1 例 3 级治疗相关不良事件(中性粒细胞下降,15 天恢复),无停药或中断,最常见为首次给药后的流感样症状。公司计划 2027 年中向 FDA 递交上市申请,ECLIPSE 3 等其余关键研究 2027Q1 读出。同场公布的 II 期 SOLSTICE 扩展数据显示,完成 96 周治疗的 28/28 例全部病毒不可检出,89%(24/27)肝硬度改善或稳定;更值得注意的是有限疗程探索——10 例(其中 7 例肝硬化)在病毒不可检出 ≥96 周后停药,全部达 SVR12、7 例达 SVR24、1 例达 SVR48,无病毒反弹与 ALT 升高,首次为「停药后治愈」提供了早期人体证据。
其余临床与批准:甘李药业 bofanglutide(GZR18)GRADUAL-3 3b 期达标,完成 52 周双周给药后转为每月一次维持 24 周,24 mg/48 mg 组体重分别 +0.41%/-0.12%,安慰剂组回升 8.52%(均 p<0.0001),为「月制剂维持减重」提供了首个 III 期级证据。腾盛博药 ENRICH 2b 更新:148 例中 41.9% 治疗结束时 HBsAg 清除、32.4% 24 周维持;基线 HBsAg 1,000—3,000 IU/mL 亚组 24 周清除率 20.8%。吉利德 seladelpar 的 IDEAL III 期在 AASLD 公布,PBC 患者主要复合终点(ALP 正常化且较基线降 ≥15%)达标,中国 NDA 正在 CDE 审评。拜耳阿舒克森(asundexian)OCEANIC-STROKE 中国亚组显示,在抗血小板治疗基础上加用可降低中国患者缺血性卒中复发风险 32%(中国入组 1,451 例)。此外,华东医药 DR10624 入选 AASLD 最新突破摘要;ACR 2026 于 11-08 口头公布 NKX019 在特发性炎性肌病中的 I/II 期 Ntrust 初步安全性、PK/PD 与活性数据(样本量小,仅作信号)。负面侧,Sarepta 停止 Elevidys 确证性 III 期入组,DMD 基因疗法在安全性阴影下的确证路径进一步收窄。
English|The headline isVir Biotechnology's Phase 3 win in hepatitis delta. ECLIPSE 1, presented orally at AASLD 2026 on 8 November, randomised 124 chronic hepatitis delta patients 2:1 to monthly subcutaneous elebsiran (siRNA) plus tobevibart (anti-HBsAg antibody) or delayed treatment from week 12. Theprimary endpoint — undetectable HDV RNA plus ALT normalisation at week 48 — was met at 44% versus 0% (p<0.0001), with the key secondary endpoint of undetectable virus at79% versus 0%; undetectable rates reached85% in cirrhotic (n=46) and 73% in non-cirrhotic (n=37)patients, indicating efficacy is not blunted by cirrhosis. Safety was favourable: one Grade 3 treatment-related event (neutrophil decrease, resolved in 15 days), no interruptions or discontinuations, and mostly transient flu-like symptoms after the first dose. Vir plans an FDA submission in mid-2027, with further pivotal readouts in Q1 2027. Expanded Phase 2 SOLSTICE data showed 28 of 28 patients completing 96 weeks with undetectable virus and 89% (24/27) with improved or stable liver stiffness. Most striking is thefinite-treatment exploration: ten patients (seven cirrhotic) discontinued after ≥96 weeks of undetectable virus, and all achieved SVR12, seven SVR24 and one SVR48 with no viral rebound or ALT flares — the first human signal of off-treatment cure potential.
Other readouts and approvals:Gan & Lee's bofanglutide (GZR18) hit its Phase 3b GRADUAL-3 endpoint, with monthly maintenance dosing for 24 weeks after 52 weeks of biweekly therapy holding weight at +0.41% (24 mg) and −0.12% (48 mg) versus a +8.52% rebound on placebo (both p<0.0001) — the first Phase 3-grade evidence for monthly GLP-1 weight maintenance.Brii Biosciences updated ENRICH: 41.9% of 148 patients cleared HBsAg at end of treatment and 32.4% sustained it at week 24, with 20.8% in the 1,000–3,000 IU/mL baseline subgroup.Gilead's seladelparmet the primary composite endpoint in the Phase 3 IDEAL study in PBC at AASLD, with a China NDA under CDE review.Bayer's asundexianChinese subgroup of OCEANIC-STROKE showed a 32% reduction in ischaemic stroke recurrence on top of antiplatelet therapy across 1,451 Chinese patients. Huadong Medicine's DR10624 was selected as an AASLD late-breaker, and ACR 2026 heard early Phase 1/2 Ntrust data for NKX019 in idiopathic inflammatory myopathy on 8 November (small sample; signal only). On the negative side,Sarepta stopped enrolment in the confirmatory Phase 3 trial of Elevidys, further narrowing the confirmatory path for the DMD gene therapy.五、市场与本周日历 / Market & Calendar
中文|周一早间 A 股、港股尚未开盘。上周五(11-06)医药板块结构性活跃:东方略 HPV 治疗性疫苗 III 期数据催化下复星医药、德展健康、金城医药涨停,但创业板指当日下跌 3.96%、港股创新药指数跌 2.43%,全周申万医药仍上涨 4.3%,呈「指数弱、主线强」的分化。本周确定性节点密集:11-09AASLD 与 AHA 同日闭幕(AHA 心血管读出、AASLD 乙肝/MASH 收官);11-10进博会闭幕、NRx 氯胺酮 PDUFA;11-14依沃西单抗 FDA PDUFA(本期最大单一事件)与苏州全国创新药高质量发展大会(公布医保/商保新增名单);11 月底医保双目录正式发布;12-12ASH 2026 开幕。
English|Mainland and Hong Kong markets were closed at the time of writing. On Friday 7 November, Chinese pharma was structurally active: Fosun Pharma, Dezhan Health and Jincheng Pharma hit limit-up on Orient Europharma's positive Phase 3 HPV therapeutic vaccine data, even as the ChiNext index fell 3.96% and the Hong Kong innovative-drug index lost 2.43%; the SW pharmaceutical sector still gained 4.3% for the week — a "weak index, strong theme" split. The week ahead is dense:9 Novemberbrings the joint close of AASLD and AHA;10 Novemberthe CIIE closes and NRx's ketamine PDUFA falls due;14 Novemberis the ivonescimab FDA PDUFA (the single largest catalyst) plus the Suzhou conference unveiling the new reimbursement lists;end-Novemberthe dual catalogues are published; and12 DecemberASH 2026 opens.本期核验说明 / Verification Notes
ECLIPSE 1 与 SOLSTICE 分属两项研究:前者为 III 期注册研究(124 例,主要终点为复合终点),后者为 II 期扩展(96 周及停药随访)。部分中文聚合稿将「79% 病毒不可检出」误写为「100% 治愈」,已按公司新闻稿原文口径修正。
「首版商保目录 19 种药品」为 2025 年事项,本轮 2026 版尚未公布(预计 11 月底),相关旧稿未计入本期。
康哲药业磷酸芦可替尼乳膏新加坡获批实际批准日为 11-03、公告日 11-04,早于本期信息窗,未计入。
辉瑞终止 7 个临床项目为 Q3 文件披露后由数据库周报汇总,具体终止公告分散于 10 月下旬至 11 月初,本期以「Q3 披露口径」呈现。
华东医药军采处罚依据为 11-06 军队采购网公示,属行政处罚类信息,与药品质量无关。